Compare IRT & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRT | LIVN |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2009 | 2015 |
| Metric | IRT | LIVN |
|---|---|---|
| Price | $15.94 | $61.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $20.86 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 2.4M | 913.8K |
| Earning Date | 05-12-2026 | 06-01-2026 |
| Dividend Yield | ★ 4.30% | N/A |
| EPS Growth | ★ 41.18 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $657,696,000.00 | N/A |
| Revenue This Year | $3.17 | $9.15 |
| Revenue Next Year | $3.38 | $6.67 |
| P/E Ratio | $65.85 | ★ N/A |
| Revenue Growth | ★ 2.76 | N/A |
| 52 Week Low | $15.07 | $32.48 |
| 52 Week High | $21.56 | $71.58 |
| Indicator | IRT | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 41.02 |
| Support Level | $15.07 | $49.51 |
| Resistance Level | $17.67 | $65.91 |
| Average True Range (ATR) | 0.33 | 2.36 |
| MACD | -0.07 | -0.98 |
| Stochastic Oscillator | 15.48 | 24.55 |
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.